Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Asher

Showing results (211-220 of 6,821) with videos related to

Pageof 683
Sort By:
Nature Cancer|February 5, 2022
Cancer drug approvals and setbacks in 2021Asher Mullard
Nature Reviews. Drug Discovery|February 11, 2022
FDA approval of Immunocore's first-in-class TCR therapeutic broadens depth of the T cell engager platformAsher Mullard
Nature Reviews. Drug Discovery|February 11, 2022
The deadly burden of drug-resistant bacteriaAsher Mullard
Nature Reviews. Drug Discovery|February 11, 2022
FDA approves bispecific antibody for two eye diseasesAsher Mullard
Nature Reviews. Drug Discovery|February 18, 2022
Induced protein proximity drug discovery, from 30,000 feetAsher Mullard
Nature Reviews. Drug Discovery|February 12, 2024
Novartis bets US$2.9 billion on MorphoSys and an anti-myelofibrosis drugAsher Mullard
Nature Reviews. Drug Discovery|February 12, 2024
Sanofi buys Inhibrx and drug for alpha-1 antitrypsin deficiency for US$1.7 billionAsher Mullard
Nature Reviews. Drug Discovery|April 26, 2024
First-in-class IL-15 receptor agonist nabs FDA approval for bladder cancerAsher Mullard
Nature Reviews. Drug Discovery|October 8, 2025
Roche buys MASH contender for up to US$3.5 billionAsher Mullard
Homeopathy : the Journal of the Faculty of Homeopathy|September 27, 2002
Traps for young players: when the well selected remedy fails to actE Asher
Pageof 683

Showing results (211-220 of 6,821) with videos related to

Sort By:
Pageof 683
Nature Cancer|February 5, 2022
Cancer drug approvals and setbacks in 2021Asher Mullard
Nature Reviews. Drug Discovery|February 11, 2022
FDA approval of Immunocore's first-in-class TCR therapeutic broadens depth of the T cell engager platformAsher Mullard
Nature Reviews. Drug Discovery|February 11, 2022
The deadly burden of drug-resistant bacteriaAsher Mullard
Nature Reviews. Drug Discovery|February 11, 2022
FDA approves bispecific antibody for two eye diseasesAsher Mullard
Nature Reviews. Drug Discovery|February 18, 2022
Induced protein proximity drug discovery, from 30,000 feetAsher Mullard
Nature Reviews. Drug Discovery|February 12, 2024
Novartis bets US$2.9 billion on MorphoSys and an anti-myelofibrosis drugAsher Mullard
Nature Reviews. Drug Discovery|February 12, 2024
Sanofi buys Inhibrx and drug for alpha-1 antitrypsin deficiency for US$1.7 billionAsher Mullard
Nature Reviews. Drug Discovery|April 26, 2024
First-in-class IL-15 receptor agonist nabs FDA approval for bladder cancerAsher Mullard
Nature Reviews. Drug Discovery|October 8, 2025
Roche buys MASH contender for up to US$3.5 billionAsher Mullard
Homeopathy : the Journal of the Faculty of Homeopathy|September 27, 2002
Traps for young players: when the well selected remedy fails to actE Asher
Pageof 683